Welcome to our dedicated page for Bionano Genomics SEC filings (Ticker: BNGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bionano Genomics, Inc. filings document the formal disclosures of a genome-analysis company commercializing optical genome mapping solutions, diagnostic testing services, genome-analysis software and nucleic acid extraction and purification technologies. Form 8-K reports record financial results, preliminary results, material agreements, securities offerings and executive leadership changes, while registration statements describe offered common stock, pre-funded warrants and warrant securities.
Proxy materials cover board elections, executive compensation, equity-award matters, shareholder voting and governance practices. The filing record also documents capital-structure changes, Nasdaq-listed common stock disclosures, risk factors and exhibits tied to Bionano’s OGM, VIA software, Ionic system and Bionano Laboratories operations.
Bionano Genomics, Inc. reported that its Chief Medical Officer, Alka Chaubey, Ph.D., has resigned. The resignation was submitted on June 2, 2026 and will be effective July 5, 2026. The company is incorporated in Delaware and its common stock trades on the Nasdaq Capital Market under the symbol BNGO.
Bionano Genomics, Inc. general counsel Jonathan V. Dixon reported a routine tax-related share withholding. When a restricted stock unit (RSU) award vested on June 3, 2026, the company withheld 24 shares of common stock at $1.30 per share to cover tax obligations. After this non-market disposition, Dixon directly holds 239 common shares.
Bionano Genomics Chief Operating Officer Mark Oldakowski reported a small tax-related share disposition. On June 3, 2026, the company withheld 27 shares of common stock at $1.30 per share to cover his tax obligations on a restricted stock unit (RSU) award that vested the same day. This was not an open-market trade. After the withholding, he directly owns 868 shares of common stock.
Bionano Genomics, Inc. Chief Medical Officer Alka Chaubey reported a routine tax-related share withholding. On shares that vested from a prior restricted stock unit (RSU) award on June 3, 2026, the company withheld 24 shares of common stock at $1.30 per share to cover tax obligations, rather than issuing those shares. After this tax-withholding disposition, Chaubey directly holds 620 shares of Bionano Genomics common stock.
Bionano Genomics, Inc. Principal Accounting Officer Mark Adamchak reported a small, routine tax-related share withholding. On June 3, 2026, the company withheld 7 shares of common stock at $1.30 per share to cover tax obligations when an RSU award vested. After this non-market disposition, Adamchak directly holds 253 shares of common stock.
Bionano Genomics has fully repaid its Senior Secured Convertible Debentures, removing all secured debt from its balance sheet. The company used cash on hand to retire and cancel debentures with an aggregate face value of $20,000,000, originally issued in May 2024 and repaid at their scheduled maturity on May 26, 2026.
All liens on Bionano’s assets and the associated restrictive covenants have been terminated, which the company says provides meaningfully greater financial and operational flexibility. Management describes the debt retirement as a significant milestone that simplifies the financial profile and allows more focus on growing adoption of its optical genome mapping solutions and executing its commercial strategy.
Bionano Genomics director Aleksandar Rajkovic received a grant of stock options for 9,149 shares of common stock at an exercise price of $1.19 per share. These options vest in equal monthly installments over 12 months and expire on May 13, 2036.
The award is standard equity compensation, not an open‑market stock purchase or sale. The options will be fully vested by the company’s next annual stockholder meeting or upon a qualifying Change of Control, assuming continuous service through each vesting date.
Bionano Genomics, Inc. director Yvonne Linney received a grant of stock options covering 9,149 shares of common stock. The options have an exercise price of $1.19 per share and expire on May 13, 2036.
The award vests in equal monthly installments over 12 months, and will be fully vested by the company’s next annual stockholder meeting, subject to her continuous service. The options also vest in full upon a Change of Control as defined in the company’s 2018 equity incentive plan.
Bionano Genomics director Kristiina Vuori, MD received a new stock option grant. She was awarded options covering 9,149 shares of common stock at an exercise price of $1.19 per share. These options are held directly and represent compensation rather than an open-market purchase.
The options will vest in equal monthly installments over 12 months following the grant date and will in any case be fully vested by the company’s next annual stockholder meeting, so long as her continuous service continues through each vesting date. The award also fully vests upon a Change of Control under the company’s 2018 equity incentive plan, and expires on May 13, 2036 if not exercised.
Bionano Genomics director Christopher J. Twomey received a grant of stock options covering 9,149 shares of common stock at an exercise price of $1.19 per share. These options vest in equal monthly installments over 12 months and will be fully vested by the next annual stockholder meeting or upon a qualifying change of control. Following this grant, he holds options on 9,149 shares that expire on May 13, 2036.